These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 25897551

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X, Hu J.
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes.
    Med Lett Drugs Ther; 2020 Jun 01; 62(1599):88. PubMed ID: 32555117
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R.
    Curr Med Res Opin; 2015 May 01; 31(5):901-11. PubMed ID: 25775379
    [Abstract] [Full Text] [Related]

  • 12. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ.
    Clin Ther; 2013 Jan 01; 35(1):A33-42. PubMed ID: 23328275
    [Abstract] [Full Text] [Related]

  • 13. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.
    Glund S, Mattheus M, Runge F, Rose P, Friedrich C.
    Int J Clin Pharmacol Ther; 2017 Apr 01; 55(4):355-367. PubMed ID: 28290274
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
    Goncalves E, Bell DSH.
    Diabetes Obes Metab; 2017 Jun 01; 19(6):909-911. PubMed ID: 28176440
    [No Abstract] [Full Text] [Related]

  • 15. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
    Watada H, Yamauchi T, Yamamoto F, Taniguchi A, Yarush L, Heilmann C, Yasui A.
    Expert Opin Drug Saf; 2020 Sep 01; 19(9):1193-1202. PubMed ID: 32552153
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M, Mather A.
    Expert Rev Clin Pharmacol; 2014 May 01; 7(3):271-9. PubMed ID: 24716752
    [Abstract] [Full Text] [Related]

  • 18. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes.
    Majewski C, Bakris GL.
    Diabetes Care; 2015 Mar 01; 38(3):429-30. PubMed ID: 25715414
    [No Abstract] [Full Text] [Related]

  • 19. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.
    Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC.
    Diabetes Care; 2015 Mar 01; 38(3):394-402. PubMed ID: 25633662
    [Abstract] [Full Text] [Related]

  • 20. Results from Cardiovascular Outcome Trials in Diabetes.
    Muñoz Torres M, Muñoz Garach A.
    Endocrinol Nutr; 2016 Mar 01; 63(7):317-9. PubMed ID: 27324936
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.